Why Rare-Ultra Orphan Therapies need early Market Access planning and innovative solutions | Ascella Health
Success in launching new therapies for rare diseases (RDs) implies the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on the market. Access to RD therapies is challenging because the legal and policy frameworks may be absent, funding may be insufficient and/or payers do not see the justification with the prices for these therapies. The industry has, however, a real opportunity to partner with healthcare stakeholders. There needs to be continued support to provide the education towards payers, drive evidence-based pricing, and innovative contracting, and address the multiple hurdles of access for these unique therapies. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data on these new therapies? That is why all stakeholders need to address early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision. Podcast Participants: Jim Clement – Partner & Board Member at Coeus Holdings Donovan Quill – Executive Vice President at Terebellum
You May Also Like

Bloomberg News Now
Bloomberg

Brian Kilmeade Show
FOX News Podcasts

Durham News Today | 2 Min News | The Daily News Now!
The Daily News Now!

The Situation Room with Wolf Blitzer and Pamela Brown
CNN Podcasts

Ranch It Up Radio Show & Podcast
Jeff ”Tigger” Erhardt & Rebecca ”BEC” Wanner, Tigger & BEC

Aristegui Noticias Podcast
Sonoro, Aristegui

The Zone
Sports Radio 810 WHB

Israel Today: Ongoing War Report
Israel Today: Ongoing War Report

24/7 News: The Latest
iHeartPodcasts and TTWN

The Tucker Carlson Show
Tucker Carlson Network
Community discussion